Island expands Galidesivir IP with US Patent Grant
Filed with ASX · · 2 pages · English
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- Additional FDA Submission completed for Galidesivir
- Options exercised raises $1million
- Coalition acceptance to advance US procurement & stockpiling
- Island engages advisers to advance biodefence strategy
- FDA agrees Animal Rule pathway and PRV eligibility
Later from Island Pharmaceuticals
- Agreement with Texas Biomed for Galidesivir Program
- Ongoing engagement with the US FDA
- US Patent Granted for Galidesivir in filoviridae viruses
- Quarterly Appendix 4C and Activities Report
- FDA confirms Galidesivir approval pathway
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals